Want to join the conversation?
$BAX's research and development expenses for 1Q16 declined by 5% from the previous year quarter. This decline was as a result of foreign currency and the favorable results of the company's efforts to optimize its overall research and development expenditures and reduce infrastructure related expenses.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.